key: cord-0848892-vqx532ba
authors: Yamamoto, Norihisa; Takahashi, Yuichi; Hayashi, Shuichiro
title: Legal and Regulatory Processes for Japan’s COVID-19□Immunization Program
date: 2021-09-03
journal: Vaccine
DOI: 10.1016/j.vaccine.2021.09.002
sha: d37e1e9c91af20a6b9b99f568636407c6d86315c
doc_id: 848892
cord_uid: vqx532ba

nan

1 1

). In the review process, available data on nonclinical 59 trials, clinical trials, quality and so forth was carefully evaluated. Prior to reviewing, the 60 clinical trial for the Tozinameran COVID-19 mRNA Vaccine have been independently 61 implemented in Japan, and its data was also evaluated in the process. 

The contribution of vaccination to global health: past, present and future

The development of COVID-19 vaccines in 82 the United States: Why and how so fast?

Developing safe and effective Covid vaccines -operation warp speed's 85 strategy and approach